Indivior Reports Third Quarter 2026 Financial Results
Indivior Pharmaceuticals, Inc. announced its Q3 2026 financial results, highlighting record net revenue for SUBLOCADE and strong growth in adjusted EBITDA.
Stocks · News reference
Supernus to Combine with Indivior To Form CNS Biopharmaceutical Leader with Potential $2 Billion in Revenue
Supernus and Indivior agree to merge in an all-stock deal, targeting $2.2 billion in revenue and $125 million in synergies.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
8-K filing — Indivior Pharmaceuticals, Inc. (INDV)
Filed: 2026-10-06 AccNo: 0001104659-26-113883 Size: 230 KB Item 8.01: Other Events
Global Substance Use Disorder Treatment Market Analysis and Forecast to 2030 | Long-Acting Therapies, Telemedicine, and Drug Innovation Drive Growth
The global substance use disorder treatment market is projected to grow from $11.6 billion in 2025 to $14.6 billion by 2030, with a compound annual growth rate of 4.6%. Growth is driven by long-acting therapies, telemedicine expansion, drug innovation, and increased government interventions, though challenges include low treatment penetration and stigma.
Halper Sadeh LLC is Investigating Whether ITGR, FHB, INDV, LNTH are Obtaining Fair Deals for their Shareholders
Halper Sadeh LLC, an investor rights law firm, is investigating four companies for potential securities law violations and breaches of fiduciary duties related to their proposed transactions. The firm is examining whether shareholders are receiving fair consideration and whether insider benefits may be prioritized over ordinary shareholder interests.
8-K filing — SUPERNUS PHARMACEUTICALS, INC. (SUPN)
Filed: 2026-10-29 AccNo: 0001356576-26-000050 Size: 461 KB Item 2.02: Results of Operations and Financial Condition Item 9.01: Financial Statements and Exhibits
Indivior Reports Q3 2026 Results and Confirms Imminent Merger with Supernus
Indivior Pharmaceuticals reported its third-quarter 2026 financial results and confirmed that its merger with Supernus Pharmaceuticals is expected to close on November 2, 2026.